Appling value of impulse oscillometry in patients with chronic obstructive pulmonary disease in stable stage

doi:10.3877/cma.j.issn.1674-6902.2017.03.015

Abstract

Abstract:

Objective

To research the application value of impulse oscillometry (IOS) in patients with chronic obstructive pulmonary disease (COPD) and its correlation with conventional detecting lung function indexes.

Methods

332 cases of COPD in our hospital from January 2013 to December 2015 were selected as experimental group, these patients were divided into mild 17 cases(group A), moderate 21 cases(group B), severe 33 cases(group C), very severe 29 cases(group D). 40 health people were selected as control group. The conventional lung function indicators (FEV₁/FVC, FEV₁) and IOS indexes (ZRS, Fres, R5, X5, R20) were detected before and after treatment and the correlation between them were also analyzed.

Results

The FEV₁, FEV₁/FVC and X5 of COPD patients were significantly lower than those of the control group, the indicators such as Zrs, Fres, R5, R5-R20 and R20 in experimenta group were significantly higher than in control group, these indicators worse with the development of disease. FEV₁/FVC, FEV₁, Zrs, Fres, R5 and R5-R20 obviously improved after treatment, and the difference was statistically significant (P<0.05). FEV₁, FEV₁/FVC had a negative correlation with Zrs, Fres, R5 and R5-R20 (P<0.05), but a positive correlation with X5 (P<0.05), the closest correlation was found in FEV₁ and Fres(r=-0.765).

Conclusion

IOS and reflect the airway resistance and have a good correlation with the traditional lung function indexes. IOS can be used as a new detection technology in COPD patients.

Key words: Chronic obstructive pulmonary disease, Conventional detecting lung function, Impulse oscillometry

Dan Meng, Xiaoyan Zhang, Jianwu Zhu, Bo Zhou, Rong Yang, Qiuxia Chen. Appling value of impulse oscillometry in patients with chronic obstructive pulmonary disease in stable stage[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(03): 313-316.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.03.015

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I03/313

Figures/Tables 3

References 19

1	任成山，钱桂生. 慢性阻塞性肺疾病发病机制研究现状与展望[J/CD]. 中华肺部疾病杂志(电子版), 2009, 2(2): 104-115.
2	Lopes AJ, Mafort TT. Correlations between small airway function, ventilation distribution, and functional exercise capacity in COPD patients[J]. Lung, 2014, 192(5): 653-659.
3	Yoshimoto D, Nakano Y, Onishi K, et al. The relationship between the COPD assessment test score and airflow limitation in Japan in patients aged over 40 years with a smoking history[J]. Int J Chron Obstruct Pulmon Dis, 2014, 9: 1357-1363.
4	Yildiz F, Bingol KG, Ersu HR, et al. The evaluation of asthma and COPD awareness in Turkey (GARD Turkey Project-National control program of chronic airway diseases)[J]. Tuberk Toraks, 2013, 61(3): 175-182.
5	Jin J, Liu X, Sun Y. The prevalence of increased serum IgE and Aspergillus sensitization in patients with COPD and their association with symptoms and lung function[J]. Respir Res, 2014, 15: 130.
6	张金蓉，李惠，陈斌. 肺功能检查配合困难患者干预措施的研究[J]. 医学综述，2013, 19(24): 4595-4596.
7	de Miguel Díez J, Jiménez García R, Hernández Barrera V, et al. Trends in Self-Rated Health Status and Health Services Use in COPD Patients (2006-2012). A Spanish Population-Based Survey[J]. Lung, 193(1): 53-62.
8	Zuriarrain Reyna Y, López Neyra A, Sanz Santiago V, et al. Assessing the measurement of airway resistance by the interrupter technique [J]. Arch Argent Pediatr, 2013, 111(6): 495-501.
9	Ramlal SK, Visser FJ, Hop WC, et al. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD[J]. Pulm Pharmacol Ther, 2014, 28(2): 158-164.
10	杨思嘉，刘锦铭，刘盼盼，等. 脉冲振荡肺功能在COPD分级诊断中的应用价值[J]. 山东医药，2011, 51(16): 44-46.
11	蒋国华，江雪红，魏玉萍. 呼吸阻抗测定在慢性阻塞性肺疾病中的应用[J]. 临床肺科杂志，2010, 15(2): 209-210.
12	Komarow HD, Young M, Nelson C, et al. Vocal cord dysfunction as demonstrated by impulse oscillometry[J]. J Allergy Clin Immunol Pract, 2013, 1(4): 387-393.
13	Crim C, Celli B, Edwards LD, et al. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results[J]. Respir Med, 2011, 105(7): 1069-1078.
14	何光辉，黄民强，伍北寿，等. 脉冲震荡肺功能在稳定期COPD治疗中的应用价值[J]. 现代生物医学进展，2016, 16(11): 2099-2101.
15	Abe T, Setoguchi Y, Kono Y, et al. Effects of inhaled tiotropium plus transdermal tulobuterol versus tiotropium alone on impulse oscillation system (IOS)-assessed measures of peripheral airway resistance and reactance, lung function and quality of life in patients with COPD: a randomized crossover study[J]. Pulm Pharmacol Ther, 2011, 24(5): 617-624.
16	张连东，裴新军，谭美春，等. 慢性阻塞性肺疾病急性加重期血清瘦素与肺功能关系的临床研究[J]. 中国急救医学，2014, (8): 708-710.
17	许萍，刘晓静，徐春燕，等. 脉冲振荡技术在支气管哮喘诊断中的临床应用[J]. 重庆医学，2011, 40(1): 7-8.
18	刘长智，郑晓滨，陈超琳，等. 脉冲振荡技术在COPD与支气管哮喘鉴别诊断中的价值[J]. 临床肺科杂志，2013, 18(5): 851-853.
19	李航，蔡金龙，曲书强. 脉冲振荡技术在支气管哮喘治疗效果评价中的临床应用[J]. 临床肺科杂志，2016(1): 119-120.

分　组	FEV₁(L)	FEV₁/FVC(%)	Zrs	Fres	X5	R5	R5-R20	R20
健康组	2.75±0.44	79.91±2.46	0.31±0.05	11.35±1.76	－0.03±0.01	0.32±0.05	0.09±0.04	0.26±0.02
实验组	?	?	?	?	?	?	?	?
A	1.81±0.34	67.54±1.98	0.65±0.11	18.54±2.22	－0.23±0.03	0.45±0.09	0.19±0.09	0.35±0.03
B	1.62±0.34	62.45±1.87	0.72±0.12	21.23±2.21	－0.26±0.02	0.61±0.11	0.35±0.13	0.37±0.02
C	1.01±0.29	59.41±1.76	0.82±0.16	27.45±2.91	－0.31±0.02	0.66±0.12	0.42±0.26	0.40±0.04
D	0.81±0.25	51.08±0.99	0.91±0.16	31.77±3.18	－0.49±0.03	0.75±0.14	0.44±0.25	0.41±0.03
F值	3.986	4.014	3.762	3.875	3.374	3.132	6.986	2.674
P值	0.013	0.009	0.026	0.025	0.031	0.039	0.000	0.047

分　组	FEV₁(L)	FEV₁/FVC(%)	Zrs	Fres	X5	R5	R5-R20	R20
健康组	2.75±0.44	79.91±2.46	0.31±0.05	11.35±1.76	－0.03±0.01	0.32±0.05	0.09±0.04	0.26±0.02
实验组	?	?	?	?	?	?	?	?
A	1.81±0.34	67.54±1.98	0.65±0.11	18.54±2.22	－0.23±0.03	0.45±0.09	0.19±0.09	0.35±0.03
B	1.62±0.34	62.45±1.87	0.72±0.12	21.23±2.21	－0.26±0.02	0.61±0.11	0.35±0.13	0.37±0.02
C	1.01±0.29	59.41±1.76	0.82±0.16	27.45±2.91	－0.31±0.02	0.66±0.12	0.42±0.26	0.40±0.04
D	0.81±0.25	51.08±0.99	0.91±0.16	31.77±3.18	－0.49±0.03	0.75±0.14	0.44±0.25	0.41±0.03
F值	3.986	4.014	3.762	3.875	3.374	3.132	6.986	2.674
P值	0.013	0.009	0.026	0.025	0.031	0.039	0.000	0.047

分　组	FEV₁(L)	FEV₁/FVC(%)	Zrs	Fres	X5	R5	R5-R20	R20
健康组	2.75±0.44	79.91±2.46	0.31±0.05	11.35±1.76	－0.03±0.01	0.32±0.05	0.09±0.04	0.26±0.02
实验组	?	?	?	?	?	?	?	?
A	2.31±0.31^a	72.51±2.11^a	0.44±0.10^a	13.91±2.09^a	－0.21±0.01	0.36±0.08^a	0.14±0.10^a	0.31±0.05
B	2.12±0.22^b	70.44±1.67^b	0.51±0.09^b	15.23±1.87^b	－0.23±0.02	0.45±0.14^b	0.29±0.11^b	0.34±0.03
C	1.86±0.29^c	65.54±1.54^c	0.55±0.06^c	17.45±1.65^c	－0.29±0.01	0.53±0.20^c	0.35±0.18^c	0.36±0.04
D	1.61±0.19^d	60.08±1.11^d	0.58±0.08^d	25.73±1.45^d	－0.46±0.02	0.67±0.21^d	0.39±0.20^d	0.36±0.01
F值	3.542	4.165	2.572	4.664	8.412	2.713	4.986	3.273
P值	0.029	0.007	0.049	0.003	0.000	0.043	0.001	0.037

分　组	FEV₁(L)	FEV₁/FVC(%)	Zrs	Fres	X5	R5	R5-R20	R20
健康组	2.75±0.44	79.91±2.46	0.31±0.05	11.35±1.76	－0.03±0.01	0.32±0.05	0.09±0.04	0.26±0.02
实验组	?	?	?	?	?	?	?	?
A	2.31±0.31^a	72.51±2.11^a	0.44±0.10^a	13.91±2.09^a	－0.21±0.01	0.36±0.08^a	0.14±0.10^a	0.31±0.05
B	2.12±0.22^b	70.44±1.67^b	0.51±0.09^b	15.23±1.87^b	－0.23±0.02	0.45±0.14^b	0.29±0.11^b	0.34±0.03
C	1.86±0.29^c	65.54±1.54^c	0.55±0.06^c	17.45±1.65^c	－0.29±0.01	0.53±0.20^c	0.35±0.18^c	0.36±0.04
D	1.61±0.19^d	60.08±1.11^d	0.58±0.08^d	25.73±1.45^d	－0.46±0.02	0.67±0.21^d	0.39±0.20^d	0.36±0.01
F值	3.542	4.165	2.572	4.664	8.412	2.713	4.986	3.273
P值	0.029	0.007	0.049	0.003	0.000	0.043	0.001	0.037

参　数	FEV₁	FEV₁/FVC
Zrs	－0.541(0.002)	－0.662(0.003)
Fres	－0.765(0.008)	－0.687(0.032)
X5	0.661(0.030)	0.495(0.007)
R5	－0.496(0.010)	－0.411(0.002)
R5-R20	－0.613(0.031)	－0.609(0.023)
R20	－0.427(0.221)	－0.482(0.197)

Please choose a citation manager

Content to export